SDF-1 binding nucleic acids
The present invention is related to an L nucleic acid that binds to an SDF-1.
1. An L-nucleic acid molecule that binds an SDF-1, wherein the L-nucleic acid molecule comprise in the 5′→3′ direction a first stretch of nucleotides comprising 5′ X 1 X 2 SVNS 3′ (SEQ ID NO:77), a core nucleotide sequence comprising 5′GUGUGAUCUAGAUGUADWGGCUGWUCCUAGUYAGG 3′ (SEQ ID NO:57) and a second stretch of nucleotides comprising 5′ BVBSX 3 X 4 3′ (SEQ ID NO:78), wherein either
a) X 1 either is absent or is A, X 2 is G, X 3 is C and X 4 either is absent or is U; or
b) X 1 is absent, X 2 either is absent or is G, X 3 either is absent or is C and X 4 is absent.
2. The L-nucleic acid molecule according to claim 1 , wherein the core nucleotide comprises GUGUGAUCUAGAUGUADUGGCUGAUCCUAGUCAGG (SEQ ID NO:58).
3. The L-nucleic acid molecule according to claim 1 , wherein the first stretch of nucleotides comprises 5′ X 1 GCRWG 3′ (SEQ ID NO:59) and the second stretch of nucleotides comprises 5′ KRYSCX 4 3′ (SEQ ID NO:60), wherein X 1 is A or is absent, and X 4 is U or absent.
4. The L-nucleic acid molecule according to claim 1 , wherein the first stretch of nucleotides comprises 5′ AGCGUG 3′ and the second stretch of nucleotides comprises 5′ UACGCU 3′.
5. The L-nucleic acid molecule according to claim 1 , wherein the first stretch of nucleotides comprises 5′ GCGUG 3′ and the second stretch of nucleotides comprises 5′ UACGC 3′.
6. The L-nucleic acid molecule according to claim 1 , wherein the first stretch of nucleotides comprises 5′ SSBS 3′ (SEQ ID NO:73) and the second stretch of nucleotides comprises 5′ BVSS 3′ (SEQ ID NO:74).
7. The L-nucleic acid molecule according to claim 1 , wherein said SDF-1 is a human SDF-1.
8. The L-nucleic acid molecule according to claim 1 , wherein said SDF-1 comprises SEQ ID NO: 1.
9. The L-nucleic acid molecule according to claim 1 , wherein the L-nucleic acid molecule is an antagonist of an SDF-1.
10. The L-nucleic acid according to claim 1 , further comprising a modification.
11. The L-nucleic acid according to claim 10 , wherein said modification is a hydroxyl ethyl starch (HES) moiety or a polyethylene glycol (PEG) moiety.
12. The L-nucleic acid according to claim 10 , wherein said modification consists of a straight or a branched PEG moiety.
13. The L-nucleic acid according to claim 12 , wherein said straight or said branched PEG moiety comprises a molecular weight from 2 to 180 kD.
14. The L-nucleic acid according to claim 11 , wherein said HES moiety comprises a molecular weight from 10 to 130 kD.
15. A pharmaceutical composition comprising the L-nucleic acid according to claim 1 and a pharmaceutically acceptable excipient, a pharmaceutically active agent or combination thereof.
16. The L-nucleic acid according to claim 1 , wherein the first stretch of nucleotides comprises 5′ X 1 GCGUG 3′ (SEQ ID NO:75) and the second stretch of nucleotides comprises 5′ UACGCX 4 3′ (SEQ ID NO:76), wherein X 1 either is absent or A, and X 4 either is absent or U.
17. The L-nucleic acid according to claim 1 , wherein the first stretch of nucleotides comprises 5′ AGCGUG 3′ and the second stretch of nucleotides comprises 5′ UGCGCU 3′.
18. The L-nucleic acid according to claim 1 , wherein the first stretch of nucleotides comprises 5′ CGUG 3′ and the second stretch of nucleotides comprises 5′ UACG 3′.